Tags : Present

Henlius Present P-III Data of HLX02 (biosimilar, trastuzumab) at ESMO

Shots: The P-III HLX02-BC01 study involves assessing HLX02 vs EU-sourced trastuzumab in combination with docetaxel in a 3wks. cycle for up to 1yr. in patients in a ratio (1:1) with HER2-positive recurrent/ mBC, prior not treated with systemic treatment   Results:  Per ITT set, ORRwk24 (71.3% vs 71.4%); Per PP set, ORRwk24 (74.2% vs 73.2%); […]Read More

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio

Shots: The exploratory analyses of the P-III study evaluate the equivalent efficacy of Aybintio vs reference bevacizumab in combination with paclitaxel & carboplatin, q3w up to 6 cycles followed by Aybintio or reference bevacizumab as maintenance monothx. in 665 patients with metastatic/recurrent nsq. NSCLC Results: previous analysis demonstrate ORR in PPS (50.1% vs 44.8%); expanded […]Read More

Roche to Present New Data of Ocrevus (ocrelizumab) for Relapsing-Remitting

Shots: Roche divulges new data that demonstrate Ocrevus (ocrelizumab) is a highly effective treatment option for people with RRMS who experienced a suboptimal response to their prior DMT. In open-label P-IIIb CASTING study, 75% of patients with RRMS and suboptimal response to prior treatment had no evidence of disease activity 2yrs. after switching to Ocrevus […]Read More

Sanofi to Present New Data of its Neurology Portfolio at

Shots: Sanofi Genzyme reports the new data from the company’s neurology portfolio, to be presented at MSVirtual2020. The company will highlight new data on tolebrutinib (SAR442168), supporting its potential in modulating disabling inflammatory processes within the CNS and will provide a deeper understanding of Sanofi Genzyme’s current MS therapies and pipeline products Additionally, the company […]Read More

AstraZeneca to Present Results of Breztri Aerosphere in P-III ETHOS

Shots: The P-III ETHOS study involves assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) vs dual therapies [Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate)] with mod. to sev. COPD and a history of exacerbation(s) in the previous year A post-hoc analysis of the P-III ETHOS trial demonstrated a consistent benefit of Breztri Aerosphere in reducing the […]Read More

Takeda to Present Results of Iclusig (ponatinib) in P-II OPTIC

Shots: The P-II OPTIC study involves assessing three initial doses of Iclusig (15/30/45 mg) in 283 patients with CML in CF, or who had documented history of the presence of the T315I mutation after receiving any number of previous TKIs With an average follow-up of~ 21 mos., the interim analysis showed that maximum BCR- ABL1 […]Read More

Sanofi and Regeneron Report Positive Results of Dupixent (dupilumab) in

Shots: The P-IIIa Dupixent Eosinophilic Esophagitis study involves assessing Dupixent (N=42) (300mg weekly) v/s PBO (N=39) in 81 patients aged 12 years and older with eosinophilic esophagitis (EoE). In addition, enrolling patients for P-IIIb for extended active treatment period to continue in 28wks The P-II study results: met its co-1EPs and 2EPs in DSQ baseline […]Read More

Santhera to Present Result of DELOS & SYROS Study at

Shots: The P-III DELOS study involves assessing of Idebenone (900 mg/day) vs PBO in 64 patients with Duchenne muscular dystrophy (DMD) for 52wks. & P-II DELPHI study with 2-year extension study (DELPHI-E). SYROS study involves assessing of Idebenone (900 mg/day) in 18 patients under Expanded Access Programs (EAPs) who completed the DELOS study The P-III […]Read More

Amgen to Present Long-Term Safety-Efficacy Data of Repatha (evolocumab) in

Shots: The presentation includes a collective analysis of 10 research abstracts plus results of OSLER-1 study, assessing Repatha (evolocumab) (420mg) in hypercholesterolemia patients for up to 5 yrs. & an additional RWE of FOURIER study assessing triglycerides in patients with CV risk FOURIER P-III (Further cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated […]Read More